Outlook Therapeutics, Inc. Files 10-K/A Amendment for Fiscal Year Ended September 30, 2023

TL;DR

<b>Outlook Therapeutics, Inc. has filed an amended annual report for FY2023, confirming its reporting compliance and Nasdaq listing.</b>

AI Summary

Outlook Therapeutics, Inc. (OTLK) filed a Amended Annual Report (10-K/A) with the SEC on January 24, 2024. Outlook Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended September 30, 2023. The company is incorporated in Delaware and has its principal executive offices in Iselin, New Jersey. Common stock of Outlook Therapeutics, Inc. is traded on The Nasdaq Stock Market LLC under the ticker symbol OTLK. The filing indicates the company is not a well-known seasoned issuer and is not required to file reports pursuant to Section 13 or 15(d) of the Act. Outlook Therapeutics, Inc. has submitted all required reports for the preceding 12 months and has been subject to such filing requirements for the past 90 days.

Why It Matters

For investors and stakeholders tracking Outlook Therapeutics, Inc., this filing contains several important signals. This amended filing provides updated information for the fiscal year ending September 30, 2023, which is crucial for investors to assess the company's current financial and operational status. The confirmation of compliance with SEC filing requirements and its listing on Nasdaq reassures stakeholders about the company's adherence to regulatory standards and market accessibility.

Risk Assessment

Risk Level: low — Outlook Therapeutics, Inc. shows low risk based on this filing. The risk is low as this is an amendment to a standard annual report, confirming compliance and listing status, with no immediate negative financial or operational disclosures apparent in the header information.

Analyst Insight

Investors should review the full amended 10-K filing for detailed updates on Outlook Therapeutics' financial performance, business operations, and any new risk factors disclosed.

Key Numbers

• 2023-09-30 — Fiscal Year End (Reported fiscal year end)
• 2024-01-24 — Filing Date (Date the 10-K/A was filed)
• 001-37759 — SEC File Number (Registrant's SEC file number)
• 08830 — ZIP Code (ZIP code for principal executive offices)

Key Players & Entities

• Outlook Therapeutics, Inc. (company) — Filer and registrant name
• OTLK (company) — Trading symbol for Common Stock
• The Nasdaq Stock Market LLC (company) — Exchange where Common Stock is registered
• Delaware (company) — State of Incorporation
• Iselin, New Jersey (company) — Location of principal executive offices
• 0001649989 (company) — Central Index Key
• 38-3982704 (company) — IRS Number
• 2023-09-30 (date) — Fiscal year end date

FAQ

Industry Context

Outlook Therapeutics, Inc. operates in the biotechnology sector, focusing on the development of biologics. The company's reporting is standard for publicly traded entities in this industry.

Regulatory Implications

The company is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments (10-K/A) with the SEC.

What Investors Should Do

1. Review the full 10-K/A filing for detailed financial statements and operational updates.
2. Analyze any changes or new disclosures in the amended report compared to the original filing.
3. Monitor future SEC filings for ongoing developments and strategic announcements from Outlook Therapeutics.

Key Dates

• 2023-09-30: Fiscal Year End — End of the reporting period for the annual report.
• 2024-01-24: Filing Date — Date the 10-K/A amendment was submitted to the SEC.

Year-Over-Year Comparison

This is an amended 10-K filing for the fiscal year ended September 30, 2023, indicating updates or corrections to the original report.

Key Financial Figures

• $0.01 — 7,517 shares of common stock, par value $0.01 per share. Auditor Firm ID: 185 Audito
• $912,760 — n stock with a grant date fair value of $912,760, which was subsequently forfeited in ac

Filing Documents

• otlk-20230930x10ka.htm (10-K/A) — 536KB
• otlk-20230930xex31d3.htm (EX-31.3) — 6KB
• otlk-20230930xex31d4.htm (EX-31.4) — 6KB
• 0001558370-24-000474.txt (&nbsp;) — 779KB
• otlk-20230930.xsd (EX-101.SCH) — 3KB
• otlk-20230930_lab.xml (EX-101.LAB) — 24KB
• otlk-20230930_pre.xml (EX-101.PRE) — 15KB
• otlk-20230930x10ka_htm.xml (XML) — 8KB

Executive Compensation

Executive Compensation 6 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 13 Item 13. Certain Relationships and Related Transactions, and Director Independence 15 Item 14. Principal Accountant Fees and Services 18 PART IV. Item 15. Exhibits and Financial Statement Schedules 20 Item 16. Form 10-K Summary 24

Signatures

Signatures 25 1 Table of Contents PART III

DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Directors and Executive Officers The following table sets forth information concerning our current executive officers and directors as of January 10, 2024. There are no family relationships among any of our directors or executive officers. NAME AGE POSITION HELD WITH THE COMPANY Executive Officers Jeff Evanson 55 Chief Commercial Officer Executive Officers and Directors C. Russell Trenary III 66 President, Chief Executive Officer and Director Lawrence A. Kenyon 58 Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director Non-Employee Directors Ralph H. "Randy" Thurman 74 Executive Chairman of the Board, Director Gerd Auffarth 59 Director Julian Gangolli 66 Director Yezan Haddadin 48 Director Julia A. Haller 69 Director Kurt J. Hilzinger 63 Director Andong Huang 26 Director Faisal G. Sukhtian 39 Director Executive Officers Jeff Evanson . Mr. Evanson has served as our Chief Commercial Officer since November 2018. Mr. Evanson has led Scott Three Consulting, LLC as Founder and President since April of 2018, and from September 2014 through April 2018, served as a Managing Director in the Life Science Practice of Navigant. Prior to joining Navigant, Mr. Evanson was the Vice President and Global Commercial Head of the Pharmaceutical Franchise at Alcon, a Novartis Company from April 2010 to September 2014. Mr. Evanson serves on the board of directors of Children's HeartLink and was formerly a two-term board member of Gillette Children's Hospital in St. Paul, Minnesota, from 2008 to 2014. Mr. Evanson received his M.B.A. from the University of Minnesota, and a B.A. in Chemistry from the University of St. Thomas in St. Paul Minnesota. C. Russell Trenary III. Mr. Trenary has served as our President, Chief Executive Officer, and member of the Board of Directors, or the Board, since July 2021. He most recently was an Executive Advisor at I

EXECUTIVE COMPENSATION

ITEM 11. EXECUTIVE COMPENSATION

Executive Compensation

Executive Compensation For the year ended September 30, 2023, our named executive officers are: C. Russell Trenary III, our President and Chief Executive Officer; Jeff Evanson, our Chief Commercial Officer; and Terry Dagnon, our former Chief Operations Officer. We refer to these executive officers herein as our named executive officers. Summary Compensation Table The following table sets forth the information as to compensation awarded to, paid to or earned by our named executive officers. We did not pay any non-equity incentive plan compensation or have any non-qualified deferred compensation earnings and have omitted those columns from the table. All Other Salary Bonus Option Awards Compensation Total Name and Principal Position Year ($) ($) ($) (1) ($) (2) ($) C. Russell Trenary III 2023 600,000 — 1,147,963 (3) 10,899 1,758,862 President and Chief Executive Officer 2022 600,000 195,462 513,650 24,068 1,333,179 Jeff Evanson 2023 450,000 — 267,025 (4) 1,170 718,195 Chief Commercial Officer 2022 353,077 — 966,730 89,154 1,408,961 Terry Dagnon (5) 2023 450,000 — 267,025 (4) 11,358 728,383 Former Chief Operations Officer 2022 353,077 — 966,730 114,148 1,433,955 (1) In accordance with SEC rules, this column reflects the aggregate grant date fair value of the stock option awards granted computed in accordance with ASC 718, for stock-based compensation transactions. These amounts do not reflect the actual economic value that would be realized by the named executive officer upon the exercise of the stock options. For a discussion of the assumptions used in determining the fair value of stock 6 Table of Contents option awards in the above table and other additional information on the stock options granted, refer to Note 12 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K filed with the SEC on December 22,

View Full Filing

View this 10-K/A filing on SEC EDGAR